Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombotic Secondary Prevention After Stroke.

Hans-Christoph Diener1, Peter Ringleb

  • 1Department of Neurology, University of Essen, Hufelandstrasse 55, Essen 45122, Germany. h.diener@uni.essen.de

Current Treatment Options in Cardiovascular Medicine
|August 27, 2002
PubMed
Summary

Antiplatelet drugs significantly reduce stroke risk in TIA and ischemic stroke patients. Aspirin is effective, with low doses offering better tolerance. Combination therapies and alternatives like clopidogrel provide further options for secondary stroke prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.

Headache·2021
Same author

Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial.

Circulation·2021
Same author

Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks.

Cephalalgia : an international journal of headache·2021
Same author

Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.

Journal of arrhythmia·2021
Same author

MMW Fortschritte der Medizin·2021
Same author

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany.

Annals of neurology·2021

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antiplatelet therapy is crucial for secondary stroke prevention in patients with transient ischemic attack (TIA) or noncardiac ischemic stroke.
  • Aspirin, dipyridamole, ticlopidine, and clopidogrel are key antiplatelet agents with varying efficacy and safety profiles.
  • Managing patients already on aspirin who experience recurrent cerebrovascular events presents a clinical challenge.

Purpose of the Study:

  • To review the efficacy and safety of antiplatelet drugs for secondary stroke prevention.
  • To compare different antiplatelet agents and combination therapies.
  • To discuss management strategies for patients with recurrent TIA or stroke while on antiplatelet therapy.

Main Methods:

  • Literature review of clinical trials and guidelines on antiplatelet therapy for stroke prevention.

Related Experiment Videos

  • Analysis of efficacy data for stroke risk reduction, myocardial infarction (MI), and vascular death.
  • Evaluation of safety profiles, including bleeding complications and specific adverse events.

    • Main Results:

    • Antiplatelet drugs reduce stroke risk by 11-15% and major vascular events by 15-22%.
    • Aspirin (50-325 mg) is effective, with low doses better tolerated. Aspirin plus dipyridamole is superior to aspirin alone.
    • Clopidogrel offers a better safety profile than ticlopidine, which is reserved for aspirin-intolerant patients. Anticoagulation is recommended for cardiac embolism but not routinely for noncardiac TIA/stroke.

    Conclusions:

    • Antiplatelet therapy is a cornerstone of secondary stroke prevention.
    • Individualized treatment selection based on patient history, risk factors, and drug tolerance is essential.
    • Further research is needed to address optimal strategies for patients with recurrent events on existing therapies.